{"pub": "marketwatch", "url": "https://marketwatch.com/story/brexit-stockpiling-shows-up-in-manufacturing-data-and-bakery-results-2019-10-01", "downloaded_at": "2019-10-01 11:45:12.492743+00:00", "title": "Brexit stockpiling shows up in manufacturing data and bakery results", "language": "en", "text": "Getty Images Labour Party leader Jeremy Corbyn (right), accompanied by Labour\u2019s Faiza Shaheen, has a photograph taken with a customer at a Greggs bakery shop during a visit to Chingford in east London. Greggs on Tuesday reported slowing sales.\n\nThe extent of stockpiling ahead of a possible hard Brexit was on display in Tuesday in areas ranging from manufacturing data to a bakery\u2019s results.\n\nU.K. manufacturing PMI rose to a four-month high in September \u2014 but driven by stockpiling, IHS Markit said.\n\nLevels of output, new orders, new export business and employment fell while those for stocks or purchases and input buying volumes rose, IHS Markit said as the headline index rose to 48.3 in September from 47.4 in August.\n\nBaker Greggs GRG, -8.37% meanwhile said it was preparing for the potential impact of the U.K.\u2019s departure from the European Union \u201cby building stocks of key ingredients and equipment that could be affected by disruption to the flow of goods into the U.K.\u201d The company said it\u2019s seeing pressure on both labor and food input costs.\n\nGreggs said it was reiterating its full-year forecast as same-store sales in the 13 weeks to Sept. 28 rose 7.4%, which is slower than the 9.4% growth in the nine months to Sept. 28. \u201cThis was inevitable at some point, and whilst the company\u2019s guidance remains unchanged, this may encourage (remaining) momentum investors to look elsewhere,\u201d said analysts at Barclays of the slowing sales growth.\n\nGreggs shares tumbled 6.4%.\n\nThe FTSE 100 UKX, -0.39% more broadly declined 0.12% to 7399.39.\n\nGainers included plumbing and heating products distributor Ferguson FERG, +4.37% , which rose 4.6% as it reported a rise in pretax profit for the fiscal year on 6.1% revenue growth, and said it was outperforming the U.S. market.\n\nAstraZeneca PLC AZN, -0.92% slipped 1.7% as it said the U.S. Food and Drug Administration hadn\u2019t approved its new drug application for PT010, an inhaled treatment for chronic obstructive pulmonary disease.", "description": "The extent of stockpiling ahead of a possible hard Brexit was on display in Tuesday in areas ranging from manufacturing data to a bakery\u2019s results.", "authors": ["Steve Goldstein", "European Markets Editor"], "top_image": "http://s.marketwatch.com/public/resources/MWimages/MW-HS367_gregg__ZG_20191001054654.jpg", "published_at": "2019-10-01"}